Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Celgene's Net-Net Working Capital for the quarter that ended in Sep. 2019 was ARS-1,287.15.
The industry rank for Celgene's Net-Net Working Capital or its related term are showing as below:
BUE:CELG's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.09 * Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.
Celgene (BUE:CELG) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Celgene Net-Net Working Capital Related Terms
Celgene Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Celgene's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:CELG vs GILD, BIIB, ACT: Net-Net Working Capital Comparison
For the Drug Manufacturers - General subindustry, Celgene's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Celgene Price-to-Net-Net-Working-Capital vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Celgene's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Celgene's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of ARS-1,287.15 mean?
Celgene (BUE:CELG) has a Net-Net Working Capital of ARS-1,287.15 as of Sep. 2019. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Celgene
Is Celgene's Net-Net Working Capital too high?
Celgene's current Net-Net Working Capital is ARS-1,287.15. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's Net-Net Working Capital compare to GILD and BIIB?
Celgene's Net-Net Working Capital of ARS-1,287.15 can be compared against companies in the Drug Manufacturers industry. The industry median Net-Net Working Capital is 8.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Drug Manufacturers company?
The median Net-Net Working Capital among Drug Manufacturers companies is 8.09, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Celgene For the Drug Manufacturers industry, the median Net-Net Working Capital is 8.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Celgene's current Net-Net Working Capital is ARS-1,287.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current Net-Net Working Capital of ARS-1,287.15. The current Net-Net Working Capital is ARS-1,287.15. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Celgene (BUE:CELG), the current Net-Net Working Capital is ARS-1,287.15 as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Celgene Corp. was a biopharmaceutical company focused on discovering, developing, and commercializing therapies for cancer and inflammatory diseases. Its flagship product was Revlimid (lenalidomide), used to treat multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, which generated the majority of revenue. Other marketed drugs included Pomalyst/Imnovid, Thalomid, Abraxane, Istodax, and Otezla, the latter for psoriasis and psoriatic arthritis. The company sold primarily in the United States, Europe, and other international markets through direct sales forces and distributors, with revenue driven by product sales. Celgene invested heavily in hematology and oncology research and built a pipeline through acquisitions and partnerships, including deals involving Juno Therapeutics and Impact Biomedicines. In 2019, Bristol-Myers Squibb acquired Celgene, and Celgene ceased to exist as an independent public company.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:CELG has been successfully added to your 
